ArticlePharmaceutical research2025
The Innovation Paradox in Emerging Pharmaceutical Markets: Barriers and Opportunities for Sustainable Development.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging pharmaceutical markets like Brazil, India, and China have seen significant growth due to rising medication demand, expanding middle-class access, and government support. However, this growth often focuses on cost-driven strategies like generic drug production rather than innovation. Challenges such as fragmented regulatory systems, limited infrastructure, low R&D budgets, and dependence on imported active pharmaceutical ingredients (APIs) limit global competitiveness in drug innovation. R&D investment in these markets rarely exceeds 5% of revenue, compared to 20% in established markets, widening the innovation gap. Advanced technologies such as physiologically based pharmacokinetic (PBPK) modeling, artificial intelligence (AI), and virtual bioequivalence studies present opportunities to overcome these barriers. These tools streamline drug development, lower costs, and improve regulatory processes. For instance, a case study on generic donepezil showed that a $150,000 investment in PBPK modeling software could yield returns of 113.7% when clinical studies are required and 1,120% if a biowaiver is granted. These results demonstrate the financial and operational advantages of adopting innovative technologies, enabling faster market entry and scalability across portfolios. By embracing advanced tools, companies in emerging markets can align with global regulatory trends, enhance sustainability through resource efficiency, and improve access to affordable medicines. This approach bridges the gap between economic growth and technological leadership, fostering global competitiveness and contributing to public health advancements.
Indexed as
Identifiers
40442394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.